Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency - 18/04/21
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Abstract |
Pathogen reduction technologies (PRT) have been recommended by many regulatory authorities to minimize the residual risk of transfusion-transmitted infections associated with COVID19 convalescent plasma. While its impact on safety and its cost-effectiveness are nowadays well proven, there is theoretical concern that PRT could impact efficacy of convalescent plasma by altering concentration and/or function of the neutralizing antibodies (nAb). We review here the evidence supporting a lack of significant detrimental effect from PRTs on nAbs.
El texto completo de este artículo está disponible en PDF.Keywords : Pathogen inactivation, Pathogen reduction technologies, COVID-19 convalescent plasma, Neutralizing antibodies, Efficacy, IgG subclasses
Esquema
Vol 28 - N° 2
P. 132-134 - mai 2021 Regresar al número
Artículo precedente
- What has changed after the COVID-19 pandemic in the publication process? A look-back to “Transfusion clinique et biologique”
- O. Garraud
- How can we improve blood safety and availability in Africa?
- C. Tayou Tagny
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.